{
    "nctId": "NCT01396655",
    "briefTitle": "PET in Breast Cancer Receiving Neoadjuvant Chemotherapy",
    "officialTitle": "Analysis of Clinical Outcome, Predictive and Prognostic Factors of Therapeutic Responses in Patients Who Treated With Doxorubicin & Docetaxel Neoadjuvant Chemotherapy in Clinical Stage II or III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 78,
    "primaryOutcomeMeasure": "pathologic complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. pathologically-confirmed breast cancer by core needle biopsy,\n2. initial clinical stage II or III,\n3. objective measurable lesion,\n4. ECOG performance 0\\~2,\n5. previously untreated,\n6. adequate bone marrow, hepatic, cardiac, and renal functions\n7. age 20\\~70\n8. agreement with this trial, and written informed consent\n\nExclusion Criteria:\n\n1. history of other cancer\n2. active infection\n3. pregnancy\n4. psychologic disease\n5. uncontrolled heart diseases\n6. male",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}